Hospital
ST. Anthonys Hospital, INC.
ST. Anthonys Hospital, INC. was paid $8.94M by Medicaid between Jan 2018 and Nov 2024, across 247 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoST. ANTHONYS HOSPITAL, INC.
SAINT PETERSBURG, FL 33705
SAINT PETERSBURG, FL 33705
33aNPI1295106870assigned 10/08/2015
33bProvider typePsychiatric Hospital Unit
28Total paid$8.94M
24GClaims731,374
24DCodes billed247
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Florida
Rank by total paid#6 of 15
Median peer was paid$7.13M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 88,082 | $524K | |
| 2019 | 177,852 | $1.94M | |
| 2020 | 148,331 | $1.62M | |
| 2021 | 136,504 | $1.63M | |
| 2022 | 120,544 | $2.06M | |
| 2023 | 47,036 | $903K | |
| 2024incomplete | 13,025 | $263K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 25,795 | 20,154 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 22,670 | 16,977 | $1.10M |
| 80053 | Comprehensive metabolic panel | 11% | 44,414 | 28,803 | $968K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 14,943 | 12,256 | $760K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 8,400 | 6,479 | $448K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 4,429 | 3,684 | $418K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.8% | 8,030 | 6,372 | $340K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.6% | 3,511 | 1,389 | $237K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 5,990 | 1,615 | $229K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 2,033 | 1,632 | $171K |
| G0378 | Hospital observation service, per hour | 1.8% | 22,791 | 8,822 | $161K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.7% | 12,244 | 7,674 | $154K |
235 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 1,513 | $130K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 4,985 | $125K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,194 | $122K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,976 | $115K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 4,847 | $111K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 2,444 | $110K |
| 80047 | 1.0% | 7,453 | $92K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 1,131 | $82K |
| 81025 | <1% | 7,273 | $78K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,315 | $76K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,486 | $72K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,358 | $71K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,175 | $69K |
| 84484 | <1% | 23,510 | $68K | |
| 82948 | <1% | 24,898 | $63K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,421 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 58,230 | $55K |
| 97161 | <1% | 1,198 | $54K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,046 | $49K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,315 | $47K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,195 | $47K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,402 | $35K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 186 | $34K |
| 96415 | <1% | 665 | $33K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,993 | $33K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 791 | $30K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,309 | $29K |
| 87070 | <1% | 1,364 | $28K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,723 | $28K |
| C1729 | Catheter, drainage | <1% | 222 | $27K |
| A9270 | Non-covered item or service | <1% | 7,618 | $24K |
| 84702 | <1% | 1,167 | $23K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,275 | $23K |
| 11043 | <1% | 198 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 17,446 | $20K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,731 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,954 | $17K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 281 | $16K |
| 97162 | <1% | 436 | $16K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,814 | $16K |
| 85610 | <1% | 12,136 | $16K | |
| 73562 | <1% | 1,675 | $16K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,243 | $15K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,893 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,307 | $14K |
| 97750 | <1% | 379 | $13K | |
| 85730 | <1% | 7,152 | $12K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,945 | $12K |
| 96367 | <1% | 667 | $12K | |
| 81003 | <1% | 22,534 | $12K | |
| 87641 | <1% | 2,149 | $11K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 582 | $11K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,021 | $11K |
| 93971 | <1% | 1,192 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,104 | $10K |
| 76642 | <1% | 558 | $10K | |
| 97803 | <1% | 124 | $10K | |
| 83735 | <1% | 11,871 | $10K | |
| 77066 | Tomosynthesis, mammo | <1% | 179 | $10K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,062 | $10K |
| 80074 | <1% | 999 | $9K | |
| 86850 | <1% | 2,098 | $9K | |
| 87631 | <1% | 675 | $9K | |
| 73610 | <1% | 531 | $9K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,909 | $9K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,904 | $9K |
| 73630 | <1% | 934 | $8K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 793 | $8K |
| 73030 | <1% | 1,044 | $8K | |
| 87186 | <1% | 2,722 | $8K | |
| 93970 | <1% | 691 | $7K | |
| C1769 | Guide wire | <1% | 1,214 | $7K |
| 86900 | <1% | 2,633 | $7K | |
| 86901 | <1% | 2,634 | $7K | |
| 93017 | <1% | 307 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 947 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,676 | $7K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 365 | $7K |
| 83880 | <1% | 6,254 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,368 | $6K |
| 87077 | <1% | 3,129 | $6K | |
| 85027 | <1% | 7,428 | $5K | |
| 72110 | <1% | 720 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,081 | $5K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 263 | $5K |
| 87205 | <1% | 1,522 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 252 | $5K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,255 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 257 | $5K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 548 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,288 | $4K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 218 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 444 | $4K |
| 82330 | <1% | 15,375 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,274 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 733 | $4K |
| 73130 | <1% | 363 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 85 | $4K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 968 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,674 | $4K |
| 72100 | <1% | 443 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 216 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 698 | $3K |
| 87640 | <1% | 1,131 | $3K | |
| 73110 | <1% | 179 | $3K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 758 | $3K |
| 83615 | <1% | 641 | $3K | |
| 84145 | <1% | 1,755 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,279 | $3K |
| 82805 | <1% | 916 | $3K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 34 | $3K |
| 97802 | <1% | 28 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,402 | $3K |
| 36430 | <1% | 68 | $3K | |
| 49083 | <1% | 72 | $2K | |
| 83605 | <1% | 2,176 | $2K | |
| 83690 | <1% | 7,175 | $2K | |
| 94060 | <1% | 46 | $2K | |
| 87040 | <1% | 2,158 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,444 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,617 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,776 | $2K |
| 85018 | <1% | 479 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 262 | $2K |
| 82746 | <1% | 1,205 | $2K | |
| 82607 | <1% | 1,327 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 940 | $2K |
| 85014 | <1% | 391 | $2K | |
| 84703 | <1% | 3,674 | $2K | |
| 80061 | Lipid panel | <1% | 1,983 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 161 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,662 | $2K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 111 | $1K |
| 73502 | <1% | 599 | $1K | |
| 85380 | <1% | 2,030 | $1K | |
| 87510 | <1% | 1,929 | $1K | |
| 87660 | <1% | 1,929 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 773 | $1K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 99 | $1K |
| 76801 | <1% | 502 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,022 | $1K |
| 80164 | <1% | 693 | $1K | |
| 36591 | <1% | 148 | $1K | |
| 82077 | <1% | 2,046 | $1K | |
| 90715 | <1% | 580 | $976.12 | |
| 77065 | Tomosynthesis, mammo | <1% | 42 | $899.72 |
| 82728 | <1% | 707 | $889.25 | |
| 82550 | <1% | 2,090 | $874.94 | |
| 84100 | <1% | 992 | $844.48 | |
| 93880 | <1% | 64 | $797.78 | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,938 | $756.44 |
| 72040 | <1% | 28 | $717.59 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 286 | $704.70 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,333 | $660.76 |
| 71101 | <1% | 34 | $658.51 | |
| 71250 | <1% | 90 | $656.73 | |
| 74018 | <1% | 253 | $634.12 | |
| 81001 | <1% | 1,416 | $633.60 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 69 | $604.06 |
| 0100U | <1% | 42 | $603.25 | |
| J3490 | Unclassified drugs | <1% | 380 | $593.46 |
| 70486 | <1% | 84 | $589.04 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 288 | $583.76 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,002 | $578.22 |
| 97165 | <1% | 32 | $555.96 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 264 | $530.57 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 556 | $512.90 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,557 | $480.78 |
| 76830 | Ultrasound, transvaginal | <1% | 376 | $404.33 |
| 87075 | <1% | 166 | $379.90 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 564 | $356.51 |
| 83550 | <1% | 367 | $342.88 | |
| 83540 | <1% | 421 | $341.95 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 130 | $334.67 |
| 84439 | <1% | 454 | $324.80 | |
| 51798 | <1% | 116 | $314.43 | |
| 85652 | <1% | 1,350 | $286.88 | |
| 74022 | <1% | 213 | $276.79 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,121 | $268.64 |
| 73590 | <1% | 14 | $242.34 | |
| 70491 | <1% | 15 | $222.33 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 820 | $185.34 |
| 0240U | <1% | 203 | $182.67 | |
| 87480 | <1% | 1,941 | $173.11 | |
| 82140 | <1% | 767 | $144.31 | |
| 96523 | <1% | 17 | $137.26 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 166 | $120.91 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 197 | $113.93 |
| 72072 | <1% | 13 | $104.54 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 736 | $88.10 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 513 | $68.51 |
| 94729 | <1% | 45 | $63.71 | |
| 86140 | <1% | 708 | $60.59 | |
| 86923 | <1% | 24 | $57.19 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 114 | $54.48 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 13 | $37.29 |
| 86709 | <1% | 147 | $25.47 | |
| 97116 | <1% | 61 | $21.81 | |
| 94726 | <1% | 18 | $21.11 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 47 | $20.88 |
| 00731 | <1% | 50 | $20.83 | |
| 87400 | <1% | 40 | $19.10 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 163 | $8.44 |
| 80076 | <1% | 18 | $7.15 | |
| 82378 | <1% | 33 | $6.75 | |
| 96376 | <1% | 17 | $0.90 | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 0% | 20 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 50 | $0.00 |
| 82010 | 0% | 205 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 61 | $0.00 |
| 87481 | 0% | 80 | $0.00 | |
| 96417 | 0% | 396 | $0.00 | |
| 72131 | 0% | 58 | $0.00 | |
| 0353U | 0% | 90 | $0.00 | |
| 85045 | 0% | 31 | $0.00 | |
| 29125 | 0% | 31 | $0.00 | |
| 36573 | 0% | 12 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 41 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 16 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 65 | $0.00 |
| 90686 | 0% | 88 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 128 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 118 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 344 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 478 | $0.00 |
| 88342 | 0% | 133 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 89 | $0.00 |
| 87430 | 0% | 34 | $0.00 | |
| 96411 | 0% | 211 | $0.00 | |
| 0352U | 0% | 41 | $0.00 | |
| J9045 | Injection, carboplatin, 50 mg | 0% | 25 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 40 | $0.00 |
| 88300 | 0% | 18 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWATERS, GLENN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Bartow Regional Medical Center, INC. | Bartow, FL | $9.00M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.